Peter J. Nelson, M.D.

Collapsing glomerulopathy has become an important cause of end-stage renal disease within the last two decades. Trials are being planned to determine whether directly targeting the pathogenic proliferation of renal parenchyma in collapsing glomerulopathy may benefit patients with this clinically aggressive proliferative podocytopathy.